GenMark Diagnostics Inc. (GNMK)

6.20
0.06 0.98
NASDAQ : Health Technology
Prev Close 6.14
Open 6.14
Day Low/High 6.08 / 6.34
52 Wk Low/High 3.63 / 13.67
Volume 17.27K
Avg Volume 361.70K
Exchange NASDAQ
Shares Outstanding 55.41M
Market Cap 341.34M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

GenMark Diagnostics Enters Oversold Territory (GNMK)

GenMark Diagnostics Enters Oversold Territory (GNMK)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Short Interest Falls 15.3% For GNMK

Short Interest Falls 15.3% For GNMK

The most recent short interest data has been released for the 11/15/2017 settlement date, which shows a 1,402,210 share decrease in total short interest for GenMark Diagnostics, Inc. , to 7,784,212, a decrease of 15.26% since 10/31/2017.

GNMK INVESTOR ALERT: Law Offices Of Howard G. Smith Continues Investigation On Behalf Of GenMark Diagnostics, Inc. Investors

GNMK INVESTOR ALERT: Law Offices Of Howard G. Smith Continues Investigation On Behalf Of GenMark Diagnostics, Inc. Investors

Law Offices of Howard G. Smith continues its investigation on behalf of GenMark Diagnostics, Inc.

GenMark Diagnostics To Present At The Canaccord Genuity Medical Technologies & Diagnostics Forum

GenMark Diagnostics To Present At The Canaccord Genuity Medical Technologies & Diagnostics Forum

GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that President and Chief Executive Officer, Hany Massarany, will present at the...

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against GenMark Diagnostics, Inc. - GNMK

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against GenMark Diagnostics, Inc. - GNMK

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of purchasers of the securities of GenMark Diagnostics, Inc.

GenMark Diagnostics Reports Third Quarter 2017 Results

GenMark Diagnostics Reports Third Quarter 2017 Results

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the third quarter ended September 30, 2017.

GenMark Diagnostics Schedules Third Quarter 2017 Financial Results Conference Call For November 2, 2017

GenMark Diagnostics Schedules Third Quarter 2017 Financial Results Conference Call For November 2, 2017

GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its third quarter earnings results after market close on Thursday, November 2, 2017.

RSI Alert: GenMark Diagnostics (GNMK) Now Oversold

RSI Alert: GenMark Diagnostics (GNMK) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Oversold Conditions For GenMark Diagnostics (GNMK)

Oversold Conditions For GenMark Diagnostics (GNMK)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

GenMark Reports Second Quarter 2017 Results

GenMark Reports Second Quarter 2017 Results

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the second quarter ended June 30, 2017.

GenMark Diagnostics To Attend Canaccord Genuity's 37th Annual Growth Conference

GenMark Diagnostics To Attend Canaccord Genuity's 37th Annual Growth Conference

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that President and Chief Executive Officer, Hany Massarany, will attend the 2017...

GenMark Achieves CE Mark For Its EPlex® Blood Culture Identification Gram-Positive And Gram-Negative Panels

GenMark Achieves CE Mark For Its EPlex® Blood Culture Identification Gram-Positive And Gram-Negative Panels

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced it has achieved CE Mark under the European In-Vitro Diagnostic Devices Directive...

GenMark Diagnostics Prices Upsized Public Offering Of Common Stock

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced the upsizing and pricing of its previously announced underwritten public offering of...

GenMark Diagnostics Commences Public Offering Of Common Stock

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that it has commenced an underwritten public offering of $65,000,000 of shares of...

GenMark Receives FDA 510(k) Market Clearance For Its EPlex® Instrument And Respiratory Pathogen Panel

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has received 510(k) market clearance from the U.

GenMark Diagnostics To Present At The 2017 William Blair Growth Stock Conference

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the 2017 William Blair Growth Stock Conference in Chicago on Tuesday, June 13, 2017.

Interesting GNMK Call Options For May 19th

Investors in GenMark Diagnostics, Inc. saw new options begin trading this week, for the May 19th expiration.

GenMark Diagnostics To Present At The Bank Of America Merrill Lynch 2017 Health Care Conference

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the Bank of America Merrill Lynch 2017 Health Care Conference in Las Vegas, Nevada,...

GenMark Diagnostics Reports First Quarter 2017 Results

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the first quarter ended March 31, 2017.

CORRECTING and REPLACING GenMark Achieves CE Mark for its ePlex® Blood Culture Identification Fungal Pathogen Panel

In the fifth paragraph, first sentence, the year should read 2017 (instead of 2016).

GenMark Diagnostics Schedules First Quarter 2017 Financial Results Conference Call For May 2, 2017

GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its first quarter earnings results after market close on Tuesday, May 2, 2017.

TheStreet Quant Rating: D- (Sell)